The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic
strategy is one of the most significant advances in the treatment and prevention of …

Recognition that neurohormonal activation plays a central role in the pathogenesis of heart
failure (HF) led to the development of angiotensin converting enzyme inhibitors (ACEIs) …

Angiotensin-converting enzyme inhibitors (ACEIs) have been the cornerstone of treatment of
heart failure with reduced ejection fraction (HFrEF) for over two decades. Inhibition of …

Aims Although the focus of therapeutic intervention has been on neurohormonal pathways
thought to be harmful in heart failure (HF), such as the renin–angiotensin–aldosterone …

Heart failure (HF) is an increasingly common syndrome associated with high mortality and
economic burden, and there has been a paucity over the past decade of new …

The renin-angiotensin-aldosterone system (RAAS) is well-established and continues to be
pursued as a therapeutic target in the treatment of heart failure, predominantly due to the …

Aims The combined neprilysin/renin–angiotensin system (RAS) inhibitor sacubitril/valsartan
reduced cardiovascular death or heart failure hospitalization, cardiovascular death, and all …

Purpose The aims of this article were to review the rationale behind the development of
combined angiotensin receptor/neprilysin inhibitors (ARNIs) for the management of chronic …

Abstract Purpose of Review Numerous evidence-based medical and device therapies
proven to reduce morbidity and mortality have advanced care for heart failure with reduced …

Heart failure affects≈ 5.7 million people in the United States alone. Angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone antagonists …